Qualigen Therapeutics, Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results
13. Mai 2022 06:00 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen Therapeutics’ Partner NanoSynex to Present Technology at BioMed Israel
10. Mai 2022 09:17 ET
|
Qualigen Therapeutics, Inc.
Innovative Technology Aims to Accelerate Antimicrobial Susceptibility Test Result Times by Six-Fold CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a...
Qualigen Therapeutics to Acquire Majority Stake in Diagnostics Technology Company NanoSynex
03. Mai 2022 09:17 ET
|
Qualigen Therapeutics, Inc.
Companies to Collaborate in the Development of Innovative Diagnostics Platform to Combat “Superbugs,” a Rising Global Health Crisis CARLSBAD, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Qualigen...
Qualigen Therapeutics Appoints Shishir Sinha to Lead Diagnostics Division Following Promotion to Senior Vice President
29. April 2022 09:15 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen Therapeutics Presents Three Posters of QN-302 at American Association of Cancer Research Conference
12. April 2022 10:15 ET
|
Qualigen Therapeutics, Inc.
Data Highlights In Vivo Research and the Potential Mechanism of Action in Pancreatic and Prostate Cancers CARLSBAD, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc....
Qualigen Therapeutics Resumes Worldwide Distribution and Commercial Control Over FastPack®
05. April 2022 09:15 ET
|
Qualigen Therapeutics, Inc.
Company Prepared for Growth and Improved Profitability of its Diagnostics Business CARLSBAD, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified...
Qualigen Therapeutics, Inc. Reports Year-End 2021 Financial Results
01. April 2022 08:00 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302
30. März 2022 09:15 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen Therapeutics Announces Three Published Abstracts at American Association of Cancer Research Conference
22. März 2022 09:15 ET
|
Qualigen Therapeutics, Inc.
Abstracts Review Positive In vivo Data and the Potential Mechanism of Action for QN-302 in Pancreatic and Prostate Cancers CARLSBAD, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Qualigen...
Qualigen Therapeutics Extends Research Agreement with University of Louisville Research Foundation on RAS Program
15. März 2022 09:15 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...